In this application, we propose a comprehensive National Gene Vector Repository (NGVB) which meets all the goals stated in RFA-RR-07-002.
The Specific Aims of the NGVB are:
Specific Aim 1. Develop and Oversee a Repository of Gene Therapy Reagents. The NGVB will gather a wide variety of gene therapy reagents that will be made available to academic investigators for preclinical investigation.
Specific Aim 2. Archive Samples Collected in the Performance of Clinical Trials or Pharmacology/Toxicology Studies. The NGVB will seek to provide a safe and secure storage site for biospecimens that must be collected to maintain compliance with FDA or other regulatory agencies.
Specific Aim 3. Expansion of a Pharmacology/Toxicology Database. Indiana University has maintained a web-based Pharmacology/Toxicology Database that allows investigators to search for studies that are relevant to their area of research. The unique resource will become the model for NGVB database and allow investigators to view the design of studies already on file with the FDA.
Specific Aim 4. Serve as a Coordinating Center. The NGVB Coordinating Center will facilitate the activities within Specific Aims 1-3. In addition, it will (1) organize an External Advisory Boards; (2) develop a Policy and Procedure Manual that defines the activities of the NGVB; (3) conduct outreach activities; (4) provide a """"""""help-desk"""""""" function for investigators seeking gene therapy reagents; (5) host a new and unique bioinformatics tool that aids in vector insertion site analysis, SeqMap.
Specific Aim 5. Research on Insertional Mutagenesis. To address the research requirements of the RFA, we will build on our ongoing work in a murine gene therapy model and will compare the lentiviral vector insertion pattern with our existing database of retroviral insertions. If this system proves to be a predictor of clonal selection, it can be used to validate other, ideally in vitro, models of risk. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Animal (Mammalian and Nonmammalian) Model, and Animal and Biological Material Resource Grants (P40)
Project #
1P40RR024928-01
Application #
7468766
Study Section
Special Emphasis Panel (ZRR1-CM-9 (01))
Program Officer
Rosenblum, Daniel
Project Start
2008-06-15
Project End
2011-03-31
Budget Start
2008-06-15
Budget End
2009-03-31
Support Year
1
Fiscal Year
2008
Total Cost
$987,591
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Genetics
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Leath, Anna; Cornetta, Kenneth (2012) Developing novel lentiviral vectors into clinical products. Methods Enzymol 507:89-108
Bear, Adham S; Morgan, Richard A; Cornetta, Kenneth et al. (2012) Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther 20:246-9
Yang, Shicheng; Karne, Neel K; Goff, Stephanie L et al. (2012) A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes. Hum Gene Ther Methods 23:73-83
Shaw, Aaron; Bischof, Daniela; Jasti, Aparna et al. (2012) Using Pulmozyme DNase treatment in lentiviral vector production. Hum Gene Ther Methods 23:65-71
Walker, Joanna; Smiley, Lucy Clare; Ingram, David et al. (2011) Expression of human papillomavirus type 16 E7 is sufficient to significantly increase expression of angiogenic factors but is not sufficient to induce endothelial cell migration. Virology 410:283-90
Broxmeyer, Hal E; Lee, Man-Ryul; Hangoc, Giao et al. (2011) Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood 117:4773-7
Cornetta, Kenneth; Yao, Jing; Jasti, Aparna et al. (2011) Replication-competent lentivirus analysis of clinical grade vector products. Mol Ther 19:557-66
Fang, Juan; Jensen, Eric S; Boudreaux, Mary K et al. (2011) Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci U S A 108:9583-8
Hawkins, Troy B; Dantzer, Jessica; Peters, Brandon et al. (2011) Identifying viral integration sites using SeqMap 2.0. Bioinformatics 27:720-2
Bischof, Daniela; Cornetta, Kenneth (2010) Flexibility in cell targeting by pseudotyping lentiviral vectors. Methods Mol Biol 614:53-68